Study on how immune checkpoint drugs interact with other medicines
Part of Cancer, Digestive system, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study looks at how certain cancer drugs (called immune checkpoint inhibitors) interact with other medicines in the body. It aims to help doctors understand how to safely combine these treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with cancer and are starting treatment with an immune checkpoint inhibitor (like Keytruda, Opdivo, or similar drugs).
- You are not pregnant or breastfeeding.
- You weigh at least 110 pounds (50 kg) and your body mass index (BMI) is 35 or lower.
- You have no history of chronic liver or kidney disease, and your liver and kidney function tests are within a normal range.
- You do not have an autoimmune disorder (like lupus, Crohn's disease, or multiple sclerosis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a combination of three immune “checkpoint” medicines in people with advanced solid cancers. It aims to see how well they work and what side effects occur, including when given through a specific liver-focused treatment in eligible patients.
This trial studies whether giving immunotherapy “checkpoint inhibitor” medicine directly into the tumor area (and/or the artery feeding it), along with a chemotherapy-style drug, can work better for advanced solid tumors. It aims to boost the immune system’s ability to attack cancer while still being safe for people with measurable tumors.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This study is looking at whether a special PET scan (FDG PET/CT) and a blood test that measures ctDNA (cancer DNA in the blood) can help predict how well immune checkpoint inhibitors work in people with advanced melanoma. If you are planning to get treatment with immunotherapy drugs like ipilimumab, nivolumab, or pembrolizumab, you may be able to join.
This trial looks at how the gut microbiome (the bacteria in your digestive system) relates to outcomes when you take standard immune “checkpoint” cancer medicines. If you’re eligible, they’ll collect stool samples while you receive treatment for certain cancers.
This study looks at how well immunotherapy drugs (like checkpoint inhibitors) work for different cancers. If you are already planning to receive this type of treatment, researchers want to track your outcomes and see how you do over time.
Hear when a new Genitourinary Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.